← back to search

Tao Zhang

Liaoning Cancer Hospital & Institute · CN
Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer-related molecular mechanisms research, RNA modifications and cancer, Ferroptosis and cancer prognosis, and MicroRNA in disease regulation.
h-index
48
citations
9,314
works
557
NIH funding
primary concept
Medicine
email

Recent publications

The Bioinformatics and Experimental Analysis of CD276 for Prognosis and Immune Infiltrates in Colon Adenocarcinoma.
2026cited by 0position: contributordoi
Integrated bulk RNA-seq and scRNA-seq identification of a novel "PET-<i>SPI1</i>-<i>MYL9</i>" transcriptional axis in lung adenocarcinoma driven by polyethylene terephthalate exposure.
2026cited by 0position: contributordoi
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
˜The œLancet. Gastroenterology & hepatology 2025cited by 35position: middledoi
SERPINE1 Facilitates Metastasis in Gastric Cancer Through Anoikis Resistance and Tumor Microenvironment Remodeling.
2025cited by 12position: contributordoi
IL-4-primed human umbilical cord mesenchymal stem cells-derived extracellular vesicles facilitate recovery in spinal cord injury via the miR-21-5p/PDCD4-mediated shifting of macrophage M1/M2 polarization
Life Sciences 2025cited by 9position: middledoi
Quercetin targets the Ccl4–Ccr5 axis to relieve neuropathic pain after spinal cord injury
APL Bioengineering 2025cited by 2position: middledoi
Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study
Journal of Thoracic Oncology 2025cited by 1position: middledoi
Long-term outcomes of S-1-based chemoradiotherapy in inoperable elderly patients with esophageal carcinoma: A multicenter, randomized, phase III clinical trial
Radiotherapy and Oncology 2025cited by 1position: middledoi
Endothelial cell-secreted bone targeting exosomes promote angiogenesis coupling with osteogenesis via the PERK-ATF4-CRELD2 pathway
Stem Cell Research & Therapy 2025cited by 0position: middledoi
Pharmacological activation of GPX4 ameliorates doxorubicin-induced cardiomyopathy
Redox Biology 2024cited by 62position: lastdoi
YBX1 Promotes Esophageal Squamous Cell Carcinoma Progression via m5C‐Dependent SMOX mRNA Stabilization.
2024cited by 33position: contributordoi
Ubiquitin specific peptidase 38 epigenetically regulates KLF transcription factor 5 to augment malignant progression of lung adenocarcinoma.
2024cited by 12position: contributordoi
The influence of host genotype and gut microbial interactions on feed efficiency traits in pigs
Frontiers in Microbiology 2024cited by 10position: middledoi
Boarding pyroptosis onto nanotechnology for cancer therapy
Journal of Controlled Release 2024cited by 10position: middledoi
Sub-5 nm amorphous iridium oxide nanosheets with synergistic multi-element doping for enhanced acidic oxygen evolution electrocatalysis
Chemical Engineering Journal 2024cited by 8position: middledoi
Enhanced cisplatin chemotherapy sensitivity by self-assembled nanoparticles with Olaparib
Frontiers in Bioengineering and Biotechnology 2024cited by 6position: firstdoi
A multi-view prognostic model for diffuse large B-cell lymphoma based on kernel canonical correlation analysis and support vector machine
BMC Cancer 2024cited by 3position: middledoi
Encorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with <i>BRAF</i> V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study.
Journal of Clinical Oncology 2024cited by 1position: middledoi
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
The Lancet 2023cited by 645position: middledoi
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
The Lancet Oncology 2023cited by 408position: middledoi
Effectiveness of S-1–Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma
JAMA Network Open 2023cited by 27position: middledoi
Gut Microbiota from Short-Chain Chlorinated Paraffin-Exposed Mice Promotes Astrocyte Activation by Disrupting the Intestinal Tight Junction via Zonulin Upregulation
Journal of Agricultural and Food Chemistry 2023cited by 15position: middledoi
Good or bad: Paradox of plasminogen activator inhibitor 1 (PAI-1) in digestive system tumors.
2023cited by 11position: contributordoi
Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China
European Journal of Surgical Oncology 2023cited by 4position: middledoi
ZDHHC11B is decreased in lung adenocarcinoma and inhibits tumorigenesis via regulating epithelial-mesenchymal transition.
2023cited by 4position: contributordoi
TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR.
2022cited by 81position: contributordoi
Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients.
2022cited by 65position: contributordoi
Construction and validation of a novel coagulation-related 7-gene prognostic signature for gastric cancer.
2022cited by 12position: contributordoi
Genetic and Molecular Characterization Revealed the Prognosis Efficiency of Histone Acetylation in Pan-Digestive Cancers.
2022cited by 12position: contributordoi
TRIM65 Promotes Malignant Cell Behaviors in Triple-Negative Breast Cancer by Impairing the Stability of LATS1 Protein.
2022cited by 12position: contributordoi

Grants

MRI: Acquisition of a DC/RF Sputtering System to Support Multi-disciplinary Research on Medical Sensors and Micro-generators in WBAN
NSF1337965$230,0632013–2016PIRePORTER
Purchase of Mass Spectrometer and Nmr Accessories
NSF7606034$41,1001976–1977PIRePORTER

Frequent collaborators

· 5 papers (2022–2026)Shiwei Duan · Ningbo University3 papers (2015–2016)Jianping Ma · Ningbo University3 papers (2015–2016)Sihan Chen · Ningbo University3 papers (2015–2016)Changyi Wang · Ningbo University3 papers (2015–2016)Liyuan Han · Tulane University3 papers (2015–2016)Xiao Liu · Army Medical University2 papers (2021–2021)Xiaozhen Wang · Guangzhou University of Chinese Medicine2 papers (2021–2021)Jun Liang · Anhui Medical University2 papers (2021–2021)Zhongwei Chen · Harbin Medical University2 papers (2015–2015)Shengyuan Liu · Harbin Medical University2 papers (2015–2015)Rui Fan · The First Affiliated Hospital, Sun Yat-sen University2 papers (2015–2015)Yanfen Liu · Ningbo University2 papers (2015–2016) · 2 papers (2021–2021)Xiaolin Peng · Harbin Medical University2 papers (2015–2015)Lijun Tan · Sun Yat-sen University2 papers (2021–2021)Zhenjie Hu · Chinese Academy of Medical Sciences & Peking Union Medical College2 papers (2018–2020) · 2 papers (2021–2021)Fei Su · The First Hospital of Lanzhou University2 papers (2023–2026) · 2 papers (2021–2021)